No quarterly revenue total was found in LARIMAR THERAPEUTICS, INC.'s SEC filings.
Larimar Therapeutics, Inc. (LRMR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$44.1 million. As of Jun 30, 2026 it held $156.3 million in cash and investments and $5.0 million in total debt.
Revenue
—
Net income
$-32.78M
-25.2% vs year-ago quarter
Operating cash flow
$-44.03M
-127.2% vs year-ago quarter
Free cash flow
$-44.11M
-126.8% vs year-ago quarter
EPS
$-0.61
-154.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
103.88M
+21.4% vs year-ago quarter
Net cash
$151.31M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LRMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bala Cynwyd, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1374690
- Former names
- ZAFGEN, INC. (until May 19, 2020); ZAFGEN INC (until Nov 3, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$34.4M | -$31.1M | -$64.0M | -$49.5M | -$27.8M |
| Net income | -$32.8M | -$29.6M | -$62.5M | -$47.7M | -$26.2M |
| Diluted EPS | — | — | — | -$0.61 | -$0.41 |
| Operating cash flow | -$44.0M | -$44.6M | — | — | -$19.4M |
| Free cash flow | -$44.1M | — | — | — | -$19.4M |
| Total assets | $165.3M | $208.5M | $145.8M | $187.3M | $150.0M |
| Total liabilities | $37.9M | $50.5M | $67.8M | $48.3M | $30.1M |
| Stockholders' equity | $127.4M | $158.0M | $78.1M | $139.0M | $119.9M |
| Cash and investments | $156.3M | $200.4M | $136.9M | $175.4M | $138.5M |
| Total debt | $5.0M | $3.8M | $4.1M | $4.3M | $4.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 19, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 696 Larimar Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.